On-demand recording available
 

Though the linear mRNA COVID vaccines set the stage for the broader xRNA therapeutics industry, the industry’s push into next generation encoding RNA modalities (i.e., saRNA and circRNA) and non-prophylactic therapeutic approaches necessitates many more conversations on what shape the future RNA therapeutics regulatory paradigm should take. 

In this Advancing RNA panel discussion, we discuss the broad learnings therapeutics developers can adapt (or can’t adapt) from the previously approved mRNA vaccine products, and what an “ideal” RNA therapeutics regulatory paradigm could look like in the long-term. We also dig into best practices for working with regulators to usher encoding RNA products into the clinic, as well as current approaches for “platforming” product development.